Loading...

IKT INHIBIKASE THERAPEUTICS INC Company Mergers 8-K Filing

NHBK

KT

INHIBIKASE THERAPEUTICS INC

(IKT)

2025 8-K

Public Offering Announcement

Clinical Trial Advancement

Financial Results Announced

Financial Update

Financial Statements

Management Changes

Financial Results

Merger Agreement

Trial Results Update

Share Increase Approval

ATM Agreement Termination

Private Placement Closed

Private Placement Deal

Company Presentation

Special Meeting Approval

Annual Meeting of Stockholders

Securities Purchase Agreement

Presentation and Arbitratio...

Letter to Stockholders

Appointment of CFO

Management Change

Compliance Regained

Reverse Stock Split

Annual Meeting Results

Presentations to Investors

No Exposure to Silicon Vall...

Options Awarded

Securities Purchase Agreeme...

External Links:

On February 21, 2025, Inhibikase Therapeutics acquired CorHepta Pharmaceuticals for $15 million, issuing 4,979,101 shares as payment, and appointed Chris Cabell as President and Head of R&D.

AI Assistant

INHIBIKASE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.